RUBICONBSERubicon Research LtdHighNeutral
Announced Fri, 29 May · 17:16 IST

Audited Financial Results for the quarter and year ended March 31, 2026, and recommendation of Dividend

Revenue Growth 20pctPat Growth 25pctResults View source PDF

RUBICON · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+26.8%1-day move
₹1000.00
prior close
₹1044.30
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+3.2+5.2+4.9+8.4+26.8+27.0+29.5+22.7+17.0+19.2+37.7+37.0
Up moveDown movePending
AI summary

Rubicon Research Limited reported strong FY26 consolidated results with revenue from operations growing 36.6% to ₹17,539.56 million from ₹12,842.72 million in FY25. Net profit after tax surged 83.6% to ₹2,467.35 million compared to ₹1,343.61 million in the prior year. The company completed its IPO in October 2025, raising ₹13,775 million, with net proceeds of ₹4,712.74 million after IPO expenses. For Q4 FY26, revenue stood at ₹5,139.15 million with PAT of ₹767.85 million. The Board recommended a dividend of ₹1.50 per equity share. Deloitte Haskins & Sells LLP issued an unmodified (clean) audit opinion on both standalone and consolidated financial results. The company also completed acquisition of 65% stake in Mono Lifesciences Limited for ₹1,759.17 million post year-end.

Likely market impact

Strong financial performance with over 83% PAT growth and 36% revenue growth signals robust business momentum. The clean audit opinion and maiden dividend recommendation are positive signals for shareholders. The recent IPO and strategic acquisitions indicate growth-oriented capital deployment.